BETA


2005/0263(COD) Medical devices and active implantable medical devices

Progress: Procedure completed

RoleCommitteeRapporteurShadows
Lead ENVI ULMER Thomas (icon: PPE-DE PPE-DE)
Committee Opinion ITRE BIRUTIS Šarūnas (icon: ALDE ALDE)
Committee Opinion IMCO JÄÄTTEENMÄKI Anneli (icon: ALDE ALDE)
Lead committee dossier:
Legal Basis:
EC Treaty (after Amsterdam) EC 095

Events

2007/09/21
   Final act published in Official Journal
Details

PURPOSE: to amend provisions relating to: active implantable medical devices; medical devices and the placing of biocidal products on the market.

LEGISLATIVE ACT: Directive 2007/47/EC of the European Parliament and of the Council amending Council Directive 90/385/EEC on the approximation of the laws of the Member States relating to active implantable medical devices, Council Directive 93/42/EEC concerning medical devices and Directive 98/8/EC concerning the placing of biocidal products on the market.

BACKGROUND: in 2003 the Commission prepared and presented a Communication on the application of EU provisions relating to active implantable medical devices, medical devices and biocidal products. The conclusions of this Communication, which found support in both Council and Parliament, were that there is an urgent need to revise and amend existing legislation in order to take account of new developments.

CONTENT: the purpose of this Directive, therefore, is to amend existing Community provisions in the field of active implantable medical devices, medical devices and the placing of biocidal products on the market. The three Directives subject to amendment are:

Council Directive 90/385/EEC on the approximation of the laws of the Member States relating to active implantable medical devices.; Council Directive 93/42/EEC concerning medical devices; and Directive 98/8/EC concerning the placing of biocidal products on the market.

To ensure consistency of interpretation and implementation between provisions relating to “active implantable medical devices” and “medical devices”, the legal framework relating to:

authorised representative; the European databank; health protection measures; and medical devices incorporating stable derivates of human blood or human plasma has been extended. In addition, provisions set out in Directive 2002/98/EC setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components, has been extended to the Directive on active implantable medical devices.

The status of “software” in medical devices has been clarified. The amending Directive specifies that software specifically intended by the manufacturer to be used for one or more of the medical purposes set out in the definition of a medical devices, is indeed a medical device. Software, when used for general purposes such as healthcare setting, is not.

In other provisions the amendments introduce the following new elements:

Clarification of the term “single use” and uniform labelling in order to ensure that medical devices do not endanger the safety or health of patients. Enhanced provisions on clinical evaluation, including clarification that clinical data is generally required for all devices regardless of classification. There is the possibility to centralise data on clinical investigations in the European data bank. An explicit requirement for a post market production review system, involving incident reporting to authorities. Offering manufacturers of Class I sterile and/or measuring medical devices the option of using the full quality assurance conformity assessment module in order to provide them with more flexibility in the choice of compliance modules. Extended time period (to 15 years) for the retention of documents concerning implantable devices. Establishment of a procedure on whether or not a product falls under the definition of “medical devices”. Obliging manufacturers to designate an “authorised representative” for their devices. Emphasising the level of training and knowledge of the uses within the essential requirements. Manufacturers should place particular emphasis on the consequences of a product’s misuse and its adverse effects on the human body. Requiring manufacturers to apply adequate controls to third parties carrying out the design and manufacture of devices on their behalf. Specification of implementation procedures in accordance with the “regulatory procedure” as set out in Decision 1999/468/EEC. Mandating, within 12 months after the entry into force of this Directive, CEN and/or CENELEC to specify technical requirements and a suitable specific label for phthalate containing devices. Requiring devices that contain critical phthalates and which are used on children, pregnant and nursing women and other patients at risk, to be labelled accordingly. Requiring manufacturers to avoid the use of substances that may possibly compromise the health of patients, in particular substances which are carcinogenic, mutagenic or toxic to reproduction. They should strive to develop alternative substances or products with a lower risk potential. Excluding, from the scope of this Directive, provisions relating to in vitro diagnostic medical devices and vitro diagnostic medical devices.

ENTRY INTO FORCE: 10 October 2007.

TRANSPOTION: 21 December 2008.

APPLY: from 21 March 2010.

2007/09/05
   CSL - Draft final act
Documents
2007/09/05
   CSL - Final act signed
2007/09/04
   EP - End of procedure in Parliament
2007/07/23
   EP/CSL - Act adopted by Council after Parliament's 1st reading
2007/07/23
   CSL - Council Meeting
2007/05/03
   EC - Commission response to text adopted in plenary
Documents
2007/03/29
   EP - Results of vote in Parliament
2007/03/29
   EP - Decision by Parliament, 1st reading
Details

The European Parliament adopted the resolution drafted by Thomas Ulmer (EPP-ED, Germany) and amended the proposal put forward by the Commission amending Directive 93/42/EEC concerning medical devices and Directive 90/385/EEC concerning active implantable medical devices. The report was adopted by 645 votes in favour to 15 against with 4 abstentions.

The key amendments relate to the following:

safety: a new recital states that particular care should be taken to ensure that the reprocessing of medical devices does not endanger patients" safety or health. It is therefore necessary to provide clarification on the definition of the term "single use", uniform labelling and instructions for use. Moreover, the Commission should engage in further analysis in order to see if additional measures are appropriate to ensure a high level of protection for patients; the manufacturer should place particular emphasis on the consequences of misuse of the product and its adverse effects on the human body; differentiation from other directives: in order to ensure that the Directive could be transposed smoothly, it was crucial to distinguish clearly between this and other laws, such as the Advanced Therapies Directive, and for there to be an unambiguous definition of medical devices. The definition of the latter now includes a phrase stating that the software must be intended by its manufacturer to be used specifically for diagnostic and/or therapeutic purposes. The issue of combined products, i.e. devices which contain both human or animal tissue and material components, has been addressed. The Directive will not apply to medicinal products covered by Directive 2001/83/EC. In deciding whether a product falls under that directive or the present Directive, particular account shall be taken of the principal mode of action of the product. Nor will the directive apply to transplants or tissues or cells of human origin or to products incorporating tissues or cells of human origin, with certain prescribed exceptions; software: one very vital issue was whether 'software in its own right' should be defined as a medical device or not. Parliament inserted clarification on this point in a recital stating that it is necessary to clarify that software in its own right, when specifically intended by the manufacturer to be used for one or more of the medical purposes set out in the definition of a medical device, is a medical device. Software for general purposes when used in a healthcare setting is not a medical device. “Medical device” is redefined to include the software intended by its manufacturer to be used specifically for diagnostic and/or therapeutic purposes and necessary for its proper application intended by the manufacturer to be used for human beings for the prescribed purposes; reprocessing: the Commission shall, at the latest three years after the adoption of the Directive, submit a report to the European Parliament and to the Council on the issue of the reprocessing of medical devices in the Community. In the light of the findings of this report, the Commission shall submit any additional proposal it may deem appropriate in order to ensure a high level of health protection; comitology: the Commission will need to adapt classification rules for medical devices, to adapt the means by which the information needed to use medical devices safely and properly may be set out, to determine conditions for making certain information publicly available, to adapt the provisions on clinical investigations set out in certain Annexes, to adopt particular requirements for placing certain medical devices on the market or putting them into service, and to take decisions to withdraw such devices from the market for reasons of protection of health or safety. Those measures are of general scope and are designed to amend or supplement Directive 90/385/EEC and Directive 93/42/EEC by the modification or addition of non-essential elements, and they should be adopted in accordance with the regulatory procedure with scrutiny provided for in Article 5a of Decision 1999/468/EEC. In urgent cases, the Commission should be able to use the urgency procedure provided for in Article 5a(6) of Decision 1999/468/EC for taking decisions on withdrawal of certain medical devices from the market and for the adoption of particular requirements for placing such devices on the market or putting them into service for reasons of protection of health or safety.

Documents
2006/10/11
   EP - Committee report tabled for plenary, 1st reading/single reading
Documents
2006/10/11
   EP - Committee report tabled for plenary, 1st reading
Documents
2006/10/04
   EP - Vote in committee, 1st reading
2006/09/18
   EP - Committee opinion
Documents
2006/09/12
   EP - Amendments tabled in committee
Documents
2006/07/13
   EP - Committee opinion
Documents
2006/06/22
   EP - Committee draft report
Documents
2006/06/01
   CSL - Debate in Council
Documents
2006/06/01
   CSL - Council Meeting
2006/05/18
   EP - Referral to associated committees announced in Parliament
2006/05/17
   ESC - Economic and Social Committee: opinion, report
Documents
2006/05/02
   EP - JÄÄTTEENMÄKI Anneli (ALDE) appointed as rapporteur in IMCO
2006/02/21
   EP - ULMER Thomas (PPE-DE) appointed as rapporteur in ENVI
2006/02/21
   EP - BIRUTIS Šarūnas (ALDE) appointed as rapporteur in ITRE
2006/02/01
   EP - Committee referral announced in Parliament, 1st reading
2005/12/22
   EC - Document attached to the procedure
2005/12/22
   EC - Legislative proposal published
Details

PURPOSE : to amend Directives 93/42/EEC on medical devices and 90/385/EEC on active implantable medical devices.

PROPOSED ACT : Directive of the European Parliament and of the Council.

CONTENT : t his proposal amends Directive 93/42/EEC on medical devices by modifying current

provisions, to bring about clarity, or by introducing new provisions, seen as necessary to continue to support the protection of human health. Also, the proposal updates Directive 90/385/EEC on active implantable medical devices to make it coherent with the other Directives on medical devices.

Since its adoption in 1993, a great deal of experience has been gained on the implementation of the Directive 93/42/EEC concerning medical devices. Whilst overall the experience has been extremely positive, some experience reveals that the Directive requires improved implementation by all parties concerned. A Report on the functioning of the Medical Devices Directives was published in June of 2002 and brought forward by the Commission in its Communication (COM(2003)0386). The most important areas where improvement should be made concern:

- conformity assessment, where questions arose as to the absence of clear rules on design examination by notified bodies;

- the sufficiency and adequacy of clinical data for all classes of devices;

-post market surveillance, where better coordination of activities in the area of post market surveillance are needed;

- Notified Bodies - in relation to their competence for the tasks for which they are designated, differences in interpretation between Notified Bodies and lack of transparency in the performance, and control, of their activities;

- increased transparency to the general public in relation to the approval of devices;

- modification of Directive 90/385/EEC relating to active implantable medical devices in order to align it with the other framework Directives on medical devices.

The proposed legislative modification brings forth either additional or replacement text regarding, in particular:

Conformity assessment modules: it has been further clarified that, for the conformity assessment of class IIa and class IIb devices under Annex II notified bodies are required to assess, on a representative basis, the design documentation for the device concerned.

Clinical data and evaluation: in order to clarify and enhance the provisions on clinical evaluation, significant modification was required of Annex X concerning clinical data and its evaluation and to various references to clinical data within the provisions of the Directive, including the definition of clinical evaluation and provision for the possibility to centralise data on clinical investigations in the

European databank.

Legal certainty regarding scope: to provide a method to make binding decisions on issues arising at national level, in relation to the misinterpretation of a product as being or not being a medical device, a procedure, based on comitology, has been added to Article 13. Also, in order to clarify that it is possible for both the Directive on medical devices and the Directive on personal protective equipment to simultaneously apply to a product, such as a surgical glove, it is necessary to delete the reference in Article 1 to the Directive on personal protective equipment to allow both apply.

Measures to increase transparency: the Article on confidentiality, which previously maintained all information available under the Directive as being confidential, has been relaxed, to allow certain information on all devices to be publicly available and to allow, by comitology, a method of making other information non-confidential, such as summary information on the approval of high risk devices.

Legal basis for better coordination and communication of market surveillance activities: the market for medical devices is a global market, with a significant number of devices being imported into the EU. This has led to an increasing need to coordinate activities of national authorities when applied to issues related to the directive taking place across a number of Member States and/or third countries. Thus it is necessary to introduce a new provision on cooperation to provide a legal basis for this coordination and international activities.

Clarification regarding medicinal products/medical device provisions: devices that incorporate as an integral part a medicinal product or blood plasma derivative are required to be reviewed by a notified body in consultation with a national authority for medicines or the European Medicines Agency (EMEA) as appropriate. These provisions, which are currently contained in Annex I Section 7.4 of the Directive needed modification to reflect the experience gained over the years in their implementation, clarifying both the role of the notified body and the relevant authority.

Devices with an ancillary human tissue engineered product: provisions are made to include these devices in the scope. This mirrors the proposed Community legislation on Advanced Therapies and fills

a potential regulatory gap.

Custom-made devices: in order to better evidence the compliance of custom made device manufacturers there is now an explicit requirement for a post market vigilance system reporting to authorities, as already in place for other devices. In order to enhance patient information a requirement is introduced that the 'Statement' under Annex VIII should be also given to the patient and that it must contain the name of the manufacturer.

Amendment of other Directives: Directive 90/385/EEC on active implantable medical devices requires alignment of text on certain aspects across all three medical device directives. The Directive was the first in the series of directives on medical devices but it has not benefited to the same extent from the market experiences and developments as the Directive 93/42/EEC and the Directive 98/79/EC on in vitro diagnostic medical devices, which were adopted in later years.

To ensure consistency of interpretation and implementation of the medical device Directives and to update the Directive 90/385/EEC on active implantable medical devices in terms of health protection measures, certain aspects, such as authorised representative, the European Databank, health protection measures, and the application of the Directive 2000/70/EC on medical devices incorporating stable derivates of human blood or human plasma have to be added to Directive 90/385/EC. The latter alignment, on human blood or plasma, results in a significant body of text being inserted into the Directive.

Finally, under this regulatory reform, Directive 98/8/EC concerning the placing of biocidal products on the market needs to be modified in order to clarify that, alongside the active implantable medical devices and medical devices, in vitro diagnostic medical devices, now subject of a specific Directive, will be excluded from the scope of the biocides Directive.

Documents

Activities

Votes

Rapport Klinz A6-0332/2006 - résolution #

2006/12/12 Outcome: +: 615, 0: 20, -: 13
DE FR IT GB PL ES NL HU CZ EL PT SE BE AT DK FI IE SK LT LV EE LU SI CY MT
Total
94
72
52
69
53
45
27
21
23
22
19
17
20
17
14
14
12
14
11
8
6
6
5
4
3
icon: PPE-DE PPE-DE
239

Denmark PPE-DE

For (1)

1

Lithuania PPE-DE

1

Estonia PPE-DE

For (1)

1

Luxembourg PPE-DE

3

Slovenia PPE-DE

3

Cyprus PPE-DE

2

Malta PPE-DE

2
icon: PSE PSE
173

Czechia PSE

For (1)

1

Ireland PSE

1

Lithuania PSE

2

Estonia PSE

3

Luxembourg PSE

For (1)

1

Slovenia PSE

For (1)

1

Malta PSE

For (1)

1
icon: ALDE ALDE
80
2

Sweden ALDE

3

Austria ALDE

1

Latvia ALDE

1

Estonia ALDE

2

Luxembourg ALDE

For (1)

1

Slovenia ALDE

1

Cyprus ALDE

For (1)

1
icon: Verts/ALE Verts/ALE
40

Italy Verts/ALE

2

United Kingdom Verts/ALE

5

Spain Verts/ALE

2

Sweden Verts/ALE

For (1)

1

Belgium Verts/ALE

2

Austria Verts/ALE

2

Denmark Verts/ALE

For (1)

1

Finland Verts/ALE

For (1)

1

Latvia Verts/ALE

1

Luxembourg Verts/ALE

For (1)

1
icon: GUE/NGL GUE/NGL
36

France GUE/NGL

2

United Kingdom GUE/NGL

1

Spain GUE/NGL

For (1)

1

Netherlands GUE/NGL

2

Greece GUE/NGL

3

Portugal GUE/NGL

3

Sweden GUE/NGL

2

Denmark GUE/NGL

For (1)

1

Finland GUE/NGL

For (1)

1

Ireland GUE/NGL

1

Cyprus GUE/NGL

1
icon: UEN UEN
37

Denmark UEN

For (1)

1

Lithuania UEN

2
icon: NI NI
12

United Kingdom NI

For (1)

Abstain (1)

2

Czechia NI

1

Austria NI

1

Slovakia NI

Abstain (2)

3
icon: ITS ITS
11

United Kingdom ITS

Against (1)

1

Belgium ITS

3

Austria ITS

Abstain (1)

1
icon: IND/DEM IND/DEM
20

France IND/DEM

Against (1)

Abstain (1)

2

Poland IND/DEM

Against (1)

Abstain (1)

2

Netherlands IND/DEM

2

Czechia IND/DEM

Against (1)

1

Greece IND/DEM

1

Sweden IND/DEM

2

Denmark IND/DEM

1

Ireland IND/DEM

For (1)

1

Rapport Ulmer A6-0332/2006 - résolution #

2007/03/29 Outcome: +: 645, -: 15, 0: 4
DE FR IT ES GB PL RO BE NL CZ PT HU AT BG SE SK EL LT FI DK IE SI EE LV CY LU MT ??
Total
83
67
61
48
64
52
31
23
24
24
20
19
17
15
15
13
12
11
11
11
10
6
6
6
5
5
4
1
icon: PPE-DE PPE-DE
232
2

Ireland PPE-DE

3

Estonia PPE-DE

For (1)

1

Latvia PPE-DE

For (1)

1

Cyprus PPE-DE

2

Luxembourg PPE-DE

2

Malta PPE-DE

For (1)

1
icon: PSE PSE
179

Czechia PSE

2

Sweden PSE

2

Slovakia PSE

2

Lithuania PSE

For (1)

1

Finland PSE

1

Ireland PSE

1

Slovenia PSE

For (1)

1

Estonia PSE

3

Luxembourg PSE

For (1)

1

PSE

1
icon: ALDE ALDE
94

Hungary ALDE

1

Austria ALDE

1

Sweden ALDE

3

Ireland ALDE

For (1)

1

Slovenia ALDE

For (1)

1

Estonia ALDE

2

Cyprus ALDE

For (1)

1

Luxembourg ALDE

For (1)

1
icon: UEN UEN
40

Lithuania UEN

2

Denmark UEN

For (1)

1
icon: Verts/ALE Verts/ALE
37

Italy Verts/ALE

2

United Kingdom Verts/ALE

4

Belgium Verts/ALE

2

Austria Verts/ALE

2

Sweden Verts/ALE

For (1)

1

Finland Verts/ALE

For (1)

1

Denmark Verts/ALE

For (1)

1

Latvia Verts/ALE

1

Luxembourg Verts/ALE

For (1)

1
icon: GUE/NGL GUE/NGL
31

France GUE/NGL

2

United Kingdom GUE/NGL

1

Netherlands GUE/NGL

For (1)

1

Portugal GUE/NGL

3

Sweden GUE/NGL

2

Greece GUE/NGL

1

Finland GUE/NGL

For (1)

1

Denmark GUE/NGL

1

Cyprus GUE/NGL

2
icon: ITS ITS
19

Italy ITS

For (1)

1

United Kingdom ITS

Against (1)

1

Austria ITS

For (1)

1

Bulgaria ITS

1
icon: NI NI
12

United Kingdom NI

Against (1)

3
2

Czechia NI

1

Austria NI

1
icon: IND/DEM IND/DEM
20

France IND/DEM

2

Poland IND/DEM

3

Netherlands IND/DEM

2

Czechia IND/DEM

Abstain (1)

1

Sweden IND/DEM

2

Denmark IND/DEM

1

Ireland IND/DEM

For (1)

1

History

(these mark the time of scraping, not the official date of the change)

docs/0/docs/0/url
Old
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/sec/2005/1742/COM_SEC(2005)1742_EN.pdf
New
http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/sec/2005/1742/COM_SEC(2005)1742_EN.pdf
docs/1/docs/0/url
Old
https://dm.eesc.europa.eu/EESCDocumentSearch/Pages/redresults.aspx?k=(documenttype:AC)(documentnumber:0732)(documentyear:2006)(documentlanguage:EN)
New
https://dmsearch.eesc.europa.eu/search/public?k=(documenttype:AC)(documentnumber:0732)(documentyear:2006)(documentlanguage:EN)
docs/2/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE374.188
New
https://www.europarl.europa.eu/doceo/document/EN&reference=PE374.188
docs/3/docs/0/url
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE374.018&secondRef=02
docs/4/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE376.778
New
https://www.europarl.europa.eu/doceo/document/EN&reference=PE376.778
docs/5/docs/0/url
http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE376.323&secondRef=02
docs/6/docs/0/url
Old
http://www.europarl.europa.eu/doceo/document/A-6-2006-0332_EN.html
New
https://www.europarl.europa.eu/doceo/document/A-6-2006-0332_EN.html
docs/7/docs/0/url
/oeil/spdoc.do?i=12703&j=0&l=en
events/0/docs/0/url
Old
http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2005/0681/COM_COM(2005)0681_EN.pdf
New
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2005/0681/COM_COM(2005)0681_EN.pdf
events/1/type
Old
Committee referral announced in Parliament, 1st reading/single reading
New
Committee referral announced in Parliament, 1st reading
events/4/type
Old
Vote in committee, 1st reading/single reading
New
Vote in committee, 1st reading
events/5
date
2006-10-11T00:00:00
type
Committee report tabled for plenary, 1st reading
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/A-6-2006-0332_EN.html title: A6-0332/2006
events/5
date
2006-10-11T00:00:00
type
Committee report tabled for plenary, 1st reading/single reading
body
EP
docs
url: http://www.europarl.europa.eu/doceo/document/A-6-2006-0332_EN.html title: A6-0332/2006
events/7
date
2007-03-29T00:00:00
type
Decision by Parliament, 1st reading
body
EP
docs
url: https://www.europarl.europa.eu/doceo/document/TA-6-2007-0091_EN.html title: T6-0091/2007
summary
events/7
date
2007-03-29T00:00:00
type
Decision by Parliament, 1st reading/single reading
body
EP
docs
url: http://www.europarl.europa.eu/doceo/document/TA-6-2007-0091_EN.html title: T6-0091/2007
summary
events/11/docs/1/url
Old
https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2007:247:TOC
New
https://eur-lex.europa.eu/JOHtml.do?uri=OJ:L:2007:247:SOM:EN:HTML
procedure/instrument/1
Amending Directive 98/8/EC 1993/0465(COD)
procedure/instrument/1
Amending Directive 93/42/EEC Amending Directive 90/385/EEC Amending Directive 98/8/EC 1993/0465(COD)
committees/0
type
Responsible Committee
body
EP
associated
True
committee_full
Environment, Public Health and Food Safety
committee
ENVI
rapporteur
name: ULMER Thomas date: 2006-02-21T00:00:00 group: European People's Party (Christian Democrats) and European Democrats abbr: PPE-DE
committees/0
type
Responsible Committee
body
EP
associated
True
committee_full
Environment, Public Health and Food Safety
committee
ENVI
date
2006-02-21T00:00:00
rapporteur
name: ULMER Thomas group: European People's Party (Christian Democrats) and European Democrats abbr: PPE-DE
committees/1
type
Committee Opinion
body
EP
associated
False
committee_full
Industry, Research and Energy
committee
ITRE
rapporteur
name: BIRUTIS Šarūnas date: 2006-02-21T00:00:00 group: Alliance of Liberals and Democrats for Europe abbr: ALDE
committees/1
type
Committee Opinion
body
EP
associated
False
committee_full
Industry, Research and Energy
committee
ITRE
date
2006-02-21T00:00:00
rapporteur
name: BIRUTIS Šarūnas group: Alliance of Liberals and Democrats for Europe abbr: ALDE
committees/2
type
Committee Opinion
body
EP
associated
True
committee_full
Internal Market and Consumer Protection
committee
IMCO
rapporteur
name: JÄÄTTEENMÄKI Anneli date: 2006-05-02T00:00:00 group: Alliance of Liberals and Democrats for Europe abbr: ALDE
committees/2
type
Committee Opinion
body
EP
associated
True
committee_full
Internal Market and Consumer Protection
committee
IMCO
date
2006-05-02T00:00:00
rapporteur
name: JÄÄTTEENMÄKI Anneli group: Alliance of Liberals and Democrats for Europe abbr: ALDE
docs/6/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A6-2006-332&language=EN
New
http://www.europarl.europa.eu/doceo/document/A-6-2006-0332_EN.html
docs/7/body
EC
events/0/docs/0/url
Old
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2005/0681/COM_COM(2005)0681_EN.pdf
New
http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2005/0681/COM_COM(2005)0681_EN.pdf
events/5/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A6-2006-332&language=EN
New
http://www.europarl.europa.eu/doceo/document/A-6-2006-0332_EN.html
events/7/docs/0/url
Old
http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P6-TA-2007-91
New
http://www.europarl.europa.eu/doceo/document/TA-6-2007-0091_EN.html
activities
  • date: 2005-12-22T00:00:00 docs: url: http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2005/0681/COM_COM(2005)0681_EN.pdf title: COM(2005)0681 type: Legislative proposal published celexid: CELEX:52005PC0681:EN body: EC commission: DG: url: http://ec.europa.eu/enterprise/ title: Enterprise and Industry Commissioner: VERHEUGEN Günter type: Legislative proposal published
  • date: 2006-02-01T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP responsible: True committee: ENVI date: 2006-02-21T00:00:00 committee_full: Environment, Public Health and Food Safety (Associated committee) rapporteur: group: PPE-DE name: ULMER Thomas body: EP responsible: False committee: IMCO date: 2006-05-02T00:00:00 committee_full: Internal Market and Consumer Protection (Associated committee) rapporteur: group: ALDE name: JÄÄTTEENMÄKI Anneli body: EP responsible: False committee: ITRE date: 2006-02-21T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: ALDE name: BIRUTIS Šarūnas
  • date: 2006-05-18T00:00:00 body: EP type: Referral to associated committees announced in Parliament
  • body: CSL meeting_id: 2733 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=2733*&MEET_DATE=01/06/2006 type: Debate in Council title: 2733 council: Employment, Social Policy, Health and Consumer Affairs date: 2006-06-01T00:00:00 type: Council Meeting
  • date: 2006-10-04T00:00:00 body: EP type: Vote in committee, 1st reading/single reading committees: body: EP responsible: True committee: ENVI date: 2006-02-21T00:00:00 committee_full: Environment, Public Health and Food Safety (Associated committee) rapporteur: group: PPE-DE name: ULMER Thomas body: EP responsible: False committee: IMCO date: 2006-05-02T00:00:00 committee_full: Internal Market and Consumer Protection (Associated committee) rapporteur: group: ALDE name: JÄÄTTEENMÄKI Anneli body: EP responsible: False committee: ITRE date: 2006-02-21T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: ALDE name: BIRUTIS Šarūnas
  • date: 2006-10-11T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A6-2006-332&language=EN type: Committee report tabled for plenary, 1st reading/single reading title: A6-0332/2006 body: EP committees: body: EP responsible: True committee: ENVI date: 2006-02-21T00:00:00 committee_full: Environment, Public Health and Food Safety (Associated committee) rapporteur: group: PPE-DE name: ULMER Thomas body: EP responsible: False committee: IMCO date: 2006-05-02T00:00:00 committee_full: Internal Market and Consumer Protection (Associated committee) rapporteur: group: ALDE name: JÄÄTTEENMÄKI Anneli body: EP responsible: False committee: ITRE date: 2006-02-21T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: ALDE name: BIRUTIS Šarūnas type: Committee report tabled for plenary, 1st reading/single reading
  • date: 2007-03-29T00:00:00 docs: url: http://www.europarl.europa.eu/oeil/popups/sda.do?id=12703&l=en type: Results of vote in Parliament title: Results of vote in Parliament url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P6-TA-2007-91 type: Decision by Parliament, 1st reading/single reading title: T6-0091/2007 body: EP type: Results of vote in Parliament
  • date: 2007-07-23T00:00:00 body: CSL type: Council Meeting council: General Affairs meeting_id: 2816
  • date: 2007-07-23T00:00:00 body: EP/CSL type: Act adopted by Council after Parliament's 1st reading
  • date: 2007-09-04T00:00:00 body: EP type: End of procedure in Parliament
  • date: 2007-09-05T00:00:00 body: CSL type: Final act signed
  • date: 2007-09-21T00:00:00 type: Final act published in Official Journal docs: url: http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32007L0047 title: Directive 2007/47 url: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2007:247:TOC title: OJ L 247 21.09.2007, p. 0021
commission
  • body: EC dg: Internal Market, Industry, Entrepreneurship and SMEs commissioner: VERHEUGEN Günter
committees/0
type
Responsible Committee
body
EP
associated
True
committee_full
Environment, Public Health and Food Safety
committee
ENVI
date
2006-02-21T00:00:00
rapporteur
name: ULMER Thomas group: European People's Party (Christian Democrats) and European Democrats abbr: PPE-DE
committees/0
body
EP
responsible
True
committee
ENVI
date
2006-02-21T00:00:00
committee_full
Environment, Public Health and Food Safety (Associated committee)
rapporteur
group: PPE-DE name: ULMER Thomas
committees/1
type
Committee Opinion
body
EP
associated
False
committee_full
Industry, Research and Energy
committee
ITRE
date
2006-02-21T00:00:00
rapporteur
name: BIRUTIS Šarūnas group: Alliance of Liberals and Democrats for Europe abbr: ALDE
committees/1
body
EP
responsible
False
committee
IMCO
date
2006-05-02T00:00:00
committee_full
Internal Market and Consumer Protection (Associated committee)
rapporteur
group: ALDE name: JÄÄTTEENMÄKI Anneli
committees/2
type
Committee Opinion
body
EP
associated
True
committee_full
Internal Market and Consumer Protection
committee
IMCO
date
2006-05-02T00:00:00
rapporteur
name: JÄÄTTEENMÄKI Anneli group: Alliance of Liberals and Democrats for Europe abbr: ALDE
committees/2
body
EP
responsible
False
committee
ITRE
date
2006-02-21T00:00:00
committee_full
Industry, Research and Energy
rapporteur
group: ALDE name: BIRUTIS Šarūnas
council
  • body: CSL type: Council Meeting council: General Affairs meeting_id: 2816 url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=2816*&MEET_DATE=23/07/2007 date: 2007-07-23T00:00:00
  • body: CSL type: Council Meeting council: Employment, Social Policy, Health and Consumer Affairs meeting_id: 2733 url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=2733*&MEET_DATE=01/06/2006 date: 2006-06-01T00:00:00
docs
  • date: 2005-12-22T00:00:00 docs: url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/sec/2005/1742/COM_SEC(2005)1742_EN.pdf title: SEC(2005)1742 url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=SECfinal&an_doc=2005&nu_doc=1742 title: EUR-Lex type: Document attached to the procedure body: EC
  • date: 2006-05-17T00:00:00 docs: url: https://dm.eesc.europa.eu/EESCDocumentSearch/Pages/redresults.aspx?k=(documenttype:AC)(documentnumber:0732)(documentyear:2006)(documentlanguage:EN) title: CES0732/2006 type: Economic and Social Committee: opinion, report body: ESC
  • date: 2006-06-22T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE374.188 title: PE374.188 type: Committee draft report body: EP
  • date: 2006-07-13T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE374.018&secondRef=02 title: PE374.018 committee: ITRE type: Committee opinion body: EP
  • date: 2006-09-12T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE376.778 title: PE376.778 type: Amendments tabled in committee body: EP
  • date: 2006-09-18T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=COMPARL&mode=XML&language=EN&reference=PE376.323&secondRef=02 title: PE376.323 committee: IMCO type: Committee opinion body: EP
  • date: 2006-10-11T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A6-2006-332&language=EN title: A6-0332/2006 type: Committee report tabled for plenary, 1st reading/single reading body: EP
  • date: 2007-05-03T00:00:00 docs: url: /oeil/spdoc.do?i=12703&j=0&l=en title: SP(2007)1901/2 type: Commission response to text adopted in plenary
  • date: 2007-09-05T00:00:00 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=ADV&RESULTSET=1&DOC_ID=[%n4]%2F07&DOC_LANCD=EN&ROWSPP=25&NRROWS=500&ORDERBY=DOC_DATE+DESC title: 03612/2007/LEX type: Draft final act body: CSL
events
  • date: 2005-12-22T00:00:00 type: Legislative proposal published body: EC docs: url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2005/0681/COM_COM(2005)0681_EN.pdf title: COM(2005)0681 url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!DocNumber&lg=EN&type_doc=COMfinal&an_doc=2005&nu_doc=681 title: EUR-Lex summary: PURPOSE : to amend Directives 93/42/EEC on medical devices and 90/385/EEC on active implantable medical devices. PROPOSED ACT : Directive of the European Parliament and of the Council. CONTENT : t his proposal amends Directive 93/42/EEC on medical devices by modifying current provisions, to bring about clarity, or by introducing new provisions, seen as necessary to continue to support the protection of human health. Also, the proposal updates Directive 90/385/EEC on active implantable medical devices to make it coherent with the other Directives on medical devices. Since its adoption in 1993, a great deal of experience has been gained on the implementation of the Directive 93/42/EEC concerning medical devices. Whilst overall the experience has been extremely positive, some experience reveals that the Directive requires improved implementation by all parties concerned. A Report on the functioning of the Medical Devices Directives was published in June of 2002 and brought forward by the Commission in its Communication (COM(2003)0386). The most important areas where improvement should be made concern: - conformity assessment, where questions arose as to the absence of clear rules on design examination by notified bodies; - the sufficiency and adequacy of clinical data for all classes of devices; -post market surveillance, where better coordination of activities in the area of post market surveillance are needed; - Notified Bodies - in relation to their competence for the tasks for which they are designated, differences in interpretation between Notified Bodies and lack of transparency in the performance, and control, of their activities; - increased transparency to the general public in relation to the approval of devices; - modification of Directive 90/385/EEC relating to active implantable medical devices in order to align it with the other framework Directives on medical devices. The proposed legislative modification brings forth either additional or replacement text regarding, in particular: Conformity assessment modules: it has been further clarified that, for the conformity assessment of class IIa and class IIb devices under Annex II notified bodies are required to assess, on a representative basis, the design documentation for the device concerned. Clinical data and evaluation: in order to clarify and enhance the provisions on clinical evaluation, significant modification was required of Annex X concerning clinical data and its evaluation and to various references to clinical data within the provisions of the Directive, including the definition of clinical evaluation and provision for the possibility to centralise data on clinical investigations in the European databank. Legal certainty regarding scope: to provide a method to make binding decisions on issues arising at national level, in relation to the misinterpretation of a product as being or not being a medical device, a procedure, based on comitology, has been added to Article 13. Also, in order to clarify that it is possible for both the Directive on medical devices and the Directive on personal protective equipment to simultaneously apply to a product, such as a surgical glove, it is necessary to delete the reference in Article 1 to the Directive on personal protective equipment to allow both apply. Measures to increase transparency: the Article on confidentiality, which previously maintained all information available under the Directive as being confidential, has been relaxed, to allow certain information on all devices to be publicly available and to allow, by comitology, a method of making other information non-confidential, such as summary information on the approval of high risk devices. Legal basis for better coordination and communication of market surveillance activities: the market for medical devices is a global market, with a significant number of devices being imported into the EU. This has led to an increasing need to coordinate activities of national authorities when applied to issues related to the directive taking place across a number of Member States and/or third countries. Thus it is necessary to introduce a new provision on cooperation to provide a legal basis for this coordination and international activities. Clarification regarding medicinal products/medical device provisions: devices that incorporate as an integral part a medicinal product or blood plasma derivative are required to be reviewed by a notified body in consultation with a national authority for medicines or the European Medicines Agency (EMEA) as appropriate. These provisions, which are currently contained in Annex I Section 7.4 of the Directive needed modification to reflect the experience gained over the years in their implementation, clarifying both the role of the notified body and the relevant authority. Devices with an ancillary human tissue engineered product: provisions are made to include these devices in the scope. This mirrors the proposed Community legislation on Advanced Therapies and fills a potential regulatory gap. Custom-made devices: in order to better evidence the compliance of custom made device manufacturers there is now an explicit requirement for a post market vigilance system reporting to authorities, as already in place for other devices. In order to enhance patient information a requirement is introduced that the 'Statement' under Annex VIII should be also given to the patient and that it must contain the name of the manufacturer. Amendment of other Directives: Directive 90/385/EEC on active implantable medical devices requires alignment of text on certain aspects across all three medical device directives. The Directive was the first in the series of directives on medical devices but it has not benefited to the same extent from the market experiences and developments as the Directive 93/42/EEC and the Directive 98/79/EC on in vitro diagnostic medical devices, which were adopted in later years. To ensure consistency of interpretation and implementation of the medical device Directives and to update the Directive 90/385/EEC on active implantable medical devices in terms of health protection measures, certain aspects, such as authorised representative, the European Databank, health protection measures, and the application of the Directive 2000/70/EC on medical devices incorporating stable derivates of human blood or human plasma have to be added to Directive 90/385/EC. The latter alignment, on human blood or plasma, results in a significant body of text being inserted into the Directive. Finally, under this regulatory reform, Directive 98/8/EC concerning the placing of biocidal products on the market needs to be modified in order to clarify that, alongside the active implantable medical devices and medical devices, in vitro diagnostic medical devices, now subject of a specific Directive, will be excluded from the scope of the biocides Directive.
  • date: 2006-02-01T00:00:00 type: Committee referral announced in Parliament, 1st reading/single reading body: EP
  • date: 2006-05-18T00:00:00 type: Referral to associated committees announced in Parliament body: EP
  • date: 2006-06-01T00:00:00 type: Debate in Council body: CSL docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=2733*&MEET_DATE=01/06/2006 title: 2733
  • date: 2006-10-04T00:00:00 type: Vote in committee, 1st reading/single reading body: EP
  • date: 2006-10-11T00:00:00 type: Committee report tabled for plenary, 1st reading/single reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A6-2006-332&language=EN title: A6-0332/2006
  • date: 2007-03-29T00:00:00 type: Results of vote in Parliament body: EP docs: url: https://oeil.secure.europarl.europa.eu/oeil/popups/sda.do?id=12703&l=en title: Results of vote in Parliament
  • date: 2007-03-29T00:00:00 type: Decision by Parliament, 1st reading/single reading body: EP docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P6-TA-2007-91 title: T6-0091/2007 summary: The European Parliament adopted the resolution drafted by Thomas Ulmer (EPP-ED, Germany) and amended the proposal put forward by the Commission amending Directive 93/42/EEC concerning medical devices and Directive 90/385/EEC concerning active implantable medical devices. The report was adopted by 645 votes in favour to 15 against with 4 abstentions. The key amendments relate to the following: safety: a new recital states that particular care should be taken to ensure that the reprocessing of medical devices does not endanger patients" safety or health. It is therefore necessary to provide clarification on the definition of the term "single use", uniform labelling and instructions for use. Moreover, the Commission should engage in further analysis in order to see if additional measures are appropriate to ensure a high level of protection for patients; the manufacturer should place particular emphasis on the consequences of misuse of the product and its adverse effects on the human body; differentiation from other directives: in order to ensure that the Directive could be transposed smoothly, it was crucial to distinguish clearly between this and other laws, such as the Advanced Therapies Directive, and for there to be an unambiguous definition of medical devices. The definition of the latter now includes a phrase stating that the software must be intended by its manufacturer to be used specifically for diagnostic and/or therapeutic purposes. The issue of combined products, i.e. devices which contain both human or animal tissue and material components, has been addressed. The Directive will not apply to medicinal products covered by Directive 2001/83/EC. In deciding whether a product falls under that directive or the present Directive, particular account shall be taken of the principal mode of action of the product. Nor will the directive apply to transplants or tissues or cells of human origin or to products incorporating tissues or cells of human origin, with certain prescribed exceptions; software: one very vital issue was whether 'software in its own right' should be defined as a medical device or not. Parliament inserted clarification on this point in a recital stating that it is necessary to clarify that software in its own right, when specifically intended by the manufacturer to be used for one or more of the medical purposes set out in the definition of a medical device, is a medical device. Software for general purposes when used in a healthcare setting is not a medical device. “Medical device” is redefined to include the software intended by its manufacturer to be used specifically for diagnostic and/or therapeutic purposes and necessary for its proper application intended by the manufacturer to be used for human beings for the prescribed purposes; reprocessing: the Commission shall, at the latest three years after the adoption of the Directive, submit a report to the European Parliament and to the Council on the issue of the reprocessing of medical devices in the Community. In the light of the findings of this report, the Commission shall submit any additional proposal it may deem appropriate in order to ensure a high level of health protection; comitology: the Commission will need to adapt classification rules for medical devices, to adapt the means by which the information needed to use medical devices safely and properly may be set out, to determine conditions for making certain information publicly available, to adapt the provisions on clinical investigations set out in certain Annexes, to adopt particular requirements for placing certain medical devices on the market or putting them into service, and to take decisions to withdraw such devices from the market for reasons of protection of health or safety. Those measures are of general scope and are designed to amend or supplement Directive 90/385/EEC and Directive 93/42/EEC by the modification or addition of non-essential elements, and they should be adopted in accordance with the regulatory procedure with scrutiny provided for in Article 5a of Decision 1999/468/EEC. In urgent cases, the Commission should be able to use the urgency procedure provided for in Article 5a(6) of Decision 1999/468/EC for taking decisions on withdrawal of certain medical devices from the market and for the adoption of particular requirements for placing such devices on the market or putting them into service for reasons of protection of health or safety.
  • date: 2007-07-23T00:00:00 type: Act adopted by Council after Parliament's 1st reading body: EP/CSL
  • date: 2007-09-04T00:00:00 type: End of procedure in Parliament body: EP
  • date: 2007-09-05T00:00:00 type: Final act signed body: CSL
  • date: 2007-09-21T00:00:00 type: Final act published in Official Journal summary: PURPOSE: to amend provisions relating to: active implantable medical devices; medical devices and the placing of biocidal products on the market. LEGISLATIVE ACT: Directive 2007/47/EC of the European Parliament and of the Council amending Council Directive 90/385/EEC on the approximation of the laws of the Member States relating to active implantable medical devices, Council Directive 93/42/EEC concerning medical devices and Directive 98/8/EC concerning the placing of biocidal products on the market. BACKGROUND: in 2003 the Commission prepared and presented a Communication on the application of EU provisions relating to active implantable medical devices, medical devices and biocidal products. The conclusions of this Communication, which found support in both Council and Parliament, were that there is an urgent need to revise and amend existing legislation in order to take account of new developments. CONTENT: the purpose of this Directive, therefore, is to amend existing Community provisions in the field of active implantable medical devices, medical devices and the placing of biocidal products on the market. The three Directives subject to amendment are: Council Directive 90/385/EEC on the approximation of the laws of the Member States relating to active implantable medical devices.; Council Directive 93/42/EEC concerning medical devices; and Directive 98/8/EC concerning the placing of biocidal products on the market. To ensure consistency of interpretation and implementation between provisions relating to “active implantable medical devices” and “medical devices”, the legal framework relating to: authorised representative; the European databank; health protection measures; and medical devices incorporating stable derivates of human blood or human plasma has been extended. In addition, provisions set out in Directive 2002/98/EC setting standards of quality and safety for the collection, testing, processing, storage and distribution of human blood and blood components, has been extended to the Directive on active implantable medical devices. The status of “software” in medical devices has been clarified. The amending Directive specifies that software specifically intended by the manufacturer to be used for one or more of the medical purposes set out in the definition of a medical devices, is indeed a medical device. Software, when used for general purposes such as healthcare setting, is not. In other provisions the amendments introduce the following new elements: Clarification of the term “single use” and uniform labelling in order to ensure that medical devices do not endanger the safety or health of patients. Enhanced provisions on clinical evaluation, including clarification that clinical data is generally required for all devices regardless of classification. There is the possibility to centralise data on clinical investigations in the European data bank. An explicit requirement for a post market production review system, involving incident reporting to authorities. Offering manufacturers of Class I sterile and/or measuring medical devices the option of using the full quality assurance conformity assessment module in order to provide them with more flexibility in the choice of compliance modules. Extended time period (to 15 years) for the retention of documents concerning implantable devices. Establishment of a procedure on whether or not a product falls under the definition of “medical devices”. Obliging manufacturers to designate an “authorised representative” for their devices. Emphasising the level of training and knowledge of the uses within the essential requirements. Manufacturers should place particular emphasis on the consequences of a product’s misuse and its adverse effects on the human body. Requiring manufacturers to apply adequate controls to third parties carrying out the design and manufacture of devices on their behalf. Specification of implementation procedures in accordance with the “regulatory procedure” as set out in Decision 1999/468/EEC. Mandating, within 12 months after the entry into force of this Directive, CEN and/or CENELEC to specify technical requirements and a suitable specific label for phthalate containing devices. Requiring devices that contain critical phthalates and which are used on children, pregnant and nursing women and other patients at risk, to be labelled accordingly. Requiring manufacturers to avoid the use of substances that may possibly compromise the health of patients, in particular substances which are carcinogenic, mutagenic or toxic to reproduction. They should strive to develop alternative substances or products with a lower risk potential. Excluding, from the scope of this Directive, provisions relating to in vitro diagnostic medical devices and vitro diagnostic medical devices. ENTRY INTO FORCE: 10 October 2007. TRANSPOTION: 21 December 2008. APPLY: from 21 March 2010. docs: title: Directive 2007/47 url: https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32007L0047 title: OJ L 247 21.09.2007, p. 0021 url: https://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2007:247:TOC
other
  • body: CSL type: Council Meeting council: Former Council configuration
  • body: EC dg: url: http://ec.europa.eu/enterprise/ title: Enterprise and Industry commissioner: VERHEUGEN Günter
procedure/dossier_of_the_committee
Old
ENVI/6/32996
New
  • ENVI/6/32996
procedure/final/url
Old
http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32007L0047
New
https://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32007L0047
procedure/instrument
Old
Directive
New
  • Directive
  • Amending Directive 93/42/EEC Amending Directive 90/385/EEC Amending Directive 98/8/EC 1993/0465(COD)
procedure/subject
Old
  • 4.20.02 Medical research
  • 4.20.04 Pharmaceutical products and industry
  • 4.60.04 Consumer health
New
4.20.02
Medical research
4.20.04
Pharmaceutical products and industry
4.60.04
Consumer health
procedure/summary
  • Amending Directive 90/385/EEC
  • Amending Directive 93/42/EEC
  • Amending Directive 98/8/EC
activities/0/docs/0/url
Old
http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2005/0681/COM_COM(2005)0681_EN.pdf
New
http://www.europarl.europa.eu/RegData/docs_autres_institutions/commission_europeenne/com/2005/0681/COM_COM(2005)0681_EN.pdf
links/European Commission/title
Old
PreLex
New
EUR-Lex
activities
  • date: 2005-12-22T00:00:00 docs: url: http://www.europarl.europa.eu/registre/docs_autres_institutions/commission_europeenne/com/2005/0681/COM_COM(2005)0681_EN.pdf celexid: CELEX:52005PC0681:EN type: Legislative proposal published title: COM(2005)0681 type: Legislative proposal published body: EC commission: DG: url: http://ec.europa.eu/enterprise/ title: Enterprise and Industry Commissioner: VERHEUGEN Günter
  • date: 2006-02-01T00:00:00 body: EP type: Committee referral announced in Parliament, 1st reading/single reading committees: body: EP responsible: True committee: ENVI date: 2006-02-21T00:00:00 committee_full: Environment, Public Health and Food Safety (Associated committee) rapporteur: group: PPE-DE name: ULMER Thomas body: EP responsible: False committee: IMCO date: 2006-05-02T00:00:00 committee_full: Internal Market and Consumer Protection (Associated committee) rapporteur: group: ALDE name: JÄÄTTEENMÄKI Anneli body: EP responsible: False committee: ITRE date: 2006-02-21T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: ALDE name: BIRUTIS Šarūnas
  • date: 2006-05-18T00:00:00 body: EP type: Referral to associated committees announced in Parliament
  • body: CSL meeting_id: 2733 docs: url: http://register.consilium.europa.eu/content/out?lang=EN&typ=SET&i=SMPL&ROWSPP=25&RESULTSET=1&NRROWS=500&DOC_LANCD=EN&ORDERBY=DOC_DATE+DESC&CONTENTS=2733*&MEET_DATE=01/06/2006 type: Debate in Council title: 2733 council: Employment, Social Policy, Health and Consumer Affairs date: 2006-06-01T00:00:00 type: Council Meeting
  • date: 2006-10-04T00:00:00 body: EP type: Vote in committee, 1st reading/single reading committees: body: EP responsible: True committee: ENVI date: 2006-02-21T00:00:00 committee_full: Environment, Public Health and Food Safety (Associated committee) rapporteur: group: PPE-DE name: ULMER Thomas body: EP responsible: False committee: IMCO date: 2006-05-02T00:00:00 committee_full: Internal Market and Consumer Protection (Associated committee) rapporteur: group: ALDE name: JÄÄTTEENMÄKI Anneli body: EP responsible: False committee: ITRE date: 2006-02-21T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: ALDE name: BIRUTIS Šarūnas
  • date: 2006-10-11T00:00:00 docs: url: http://www.europarl.europa.eu/sides/getDoc.do?type=REPORT&mode=XML&reference=A6-2006-332&language=EN type: Committee report tabled for plenary, 1st reading/single reading title: A6-0332/2006 body: EP committees: body: EP responsible: True committee: ENVI date: 2006-02-21T00:00:00 committee_full: Environment, Public Health and Food Safety (Associated committee) rapporteur: group: PPE-DE name: ULMER Thomas body: EP responsible: False committee: IMCO date: 2006-05-02T00:00:00 committee_full: Internal Market and Consumer Protection (Associated committee) rapporteur: group: ALDE name: JÄÄTTEENMÄKI Anneli body: EP responsible: False committee: ITRE date: 2006-02-21T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: ALDE name: BIRUTIS Šarūnas type: Committee report tabled for plenary, 1st reading/single reading
  • date: 2007-03-29T00:00:00 docs: url: http://www.europarl.europa.eu/oeil/popups/sda.do?id=12703&l=en type: Results of vote in Parliament title: Results of vote in Parliament url: http://www.europarl.europa.eu/sides/getDoc.do?type=TA&language=EN&reference=P6-TA-2007-91 type: Decision by Parliament, 1st reading/single reading title: T6-0091/2007 body: EP type: Results of vote in Parliament
  • date: 2007-07-23T00:00:00 body: CSL type: Council Meeting council: General Affairs meeting_id: 2816
  • date: 2007-07-23T00:00:00 body: EP/CSL type: Act adopted by Council after Parliament's 1st reading
  • date: 2007-09-04T00:00:00 body: EP type: End of procedure in Parliament
  • date: 2007-09-05T00:00:00 body: CSL type: Final act signed
  • date: 2007-09-21T00:00:00 type: Final act published in Official Journal docs: url: http://eur-lex.europa.eu/smartapi/cgi/sga_doc?smartapi!celexplus!prod!CELEXnumdoc&lg=EN&numdoc=32007L0047 title: Directive 2007/47 url: http://eur-lex.europa.eu/legal-content/EN/TXT/?uri=OJ:L:2007:247:TOC title: OJ L 247 21.09.2007, p. 0021
committees
  • body: EP responsible: True committee: ENVI date: 2006-02-21T00:00:00 committee_full: Environment, Public Health and Food Safety (Associated committee) rapporteur: group: PPE-DE name: ULMER Thomas
  • body: EP responsible: False committee: IMCO date: 2006-05-02T00:00:00 committee_full: Internal Market and Consumer Protection (Associated committee) rapporteur: group: ALDE name: JÄÄTTEENMÄKI Anneli
  • body: EP responsible: False committee: ITRE date: 2006-02-21T00:00:00 committee_full: Industry, Research and Energy rapporteur: group: ALDE name: BIRUTIS Šarūnas
links
European Commission
other
  • body: CSL type: Council Meeting council: Former Council configuration
  • body: EC dg: url: http://ec.europa.eu/enterprise/ title: Enterprise and Industry commissioner: VERHEUGEN Günter
procedure
dossier_of_the_committee
ENVI/6/32996
reference
2005/0263(COD)
instrument
Directive
legal_basis
EC Treaty (after Amsterdam) EC 095
stage_reached
Procedure completed
summary
subtype
Legislation
title
Medical devices and active implantable medical devices
type
COD - Ordinary legislative procedure (ex-codecision procedure)
final
subject